Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Clinical trial NCT04762979 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04762979
- Sponsor
- Marina N Sharifi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-12
- Primary completion
- 2025-10-23
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.